Do we need to treat chronic active T cell –mediated rejection?

Chronic active T cell –mediated rejection, demonstrated by the presence of inflammation in areas of fibrosis, is associated with long-term allograft loss. Kung et al., in this issue of Kidney International, describe a series of cases of CA TCMR and analyze their clinical, molecular, and pathologic features as well as their response to therapy. Their translational study aids in understanding this diverse phenotype and provides future direction for managing these patients.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Commentary Source Type: research